MiNK Therapeutics ( INKT +17.13% ▲ ) has issued an announcement.
In response to recent investor inquiries, MiNK Therapeutics clarified that it is in active discussions with multiple parties about potential clinical combination trials involving agenT-797, its proprietary allogeneic iNKT cell therapy. The company is also exploring possible strategic minority investments, underscoring growing external interest in its platform and its applications in critical illness, while emphasizing that no binding agreements for trials or investments have yet been publicly disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.